References
- Ali I, Alharbi O. COVID-19: disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861. doi:10.1016/j.scitotenv.2020.138861
- Lin M, Xiang D, Chen X, Huo H. Role of characteristic components of Humulus lupulus in promoting human health. J Agric Food Chem. 2019;67(30):8291. doi:10.1021/acs.jafc.9b03780
- Buckwold V, Wilson R, Nalca A, et al. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res. 2004;61(1):57–62.
- Liu X, Bai J, Jiang C, et al. Therapeutic effect of Xanthohumol against highly pathogenic porcine reproductive and respiratory syndrome viruses. Vet Microbiol. 2019;238:108431. doi:10.1016/j.vetmic.2019.108431
- Liu X, Song Z, Bai J, Nauwynck H, Zhao Y, Jiang P. Xanthohumol inhibits PRRSV proliferation and alleviates oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis. Vet Res. 2019;50(1):61. doi:10.1186/s13567-019-0679-2
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
- Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. medRxiv. 2020. doi:10.1101/2020042020061861.
- DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014;88(2):913–924. doi:10.1128/JVI.02576-13
- Dorn C, Heilmann J, Hellerbrand C. Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis. Int J Clin Exp Pathol. 2012;5(1):29–36.
- Yang J-K, Jin J-M, Liu S, et al. Blood glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan, China. China. 2020. doi:10.1101/2020040820058040.
- Zhang N, Tian B, Zhao S, et al. A new formylated chalcone from Humulus lupulus with protective effect on HUVECs injury by angiotensin II. Nat Prod Res. 2019;33(5):617–621. doi:10.1080/14786419.2017.1402318
- Dostalek P, Karabin M, Jelinek L. Hop phytochemicals and their potential role in metabolic syndrome prevention and therapy. Molecules (Basel, Switzerland). 2017;22(10). doi:10.3390/molecules22101761
- Mahli A, Seitz T, Freese K, et al. Therapeutic application of micellar solubilized Xanthohumol in a western-type diet-induced mouse model of obesity, diabetes and non-alcoholic fatty liver disease. Cells. 2019;8(4):359. doi:10.3390/cells8040359
- Dorn C, Kraus B, Motyl M, et al. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res. 2010;54(Suppl S2):S205–213. doi:10.1002/mnfr.200900314
- Legette L, Karnpracha C, Reed RL, et al. Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops. Mol Nutr Food Res. 2014;58(2):248–255. doi:10.1002/mnfr.201300333
- van Breemen RB, Yuan Y, Banuvar S, et al. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol Nutr Food Res. 2014;58(10):1962–1969. doi:10.1002/mnfr.201400245